FDA Sets Restrictions for Sales of MS Drug
From Times Wire Reports
A multiple sclerosis drug withdrawn from the market last year because of a rare but life-threatening side effect will return under a restricted distribution program, officials said.
The Food and Drug Administration said it would allow sales of Tysabri to resume but required that doctors, pharmacies and patients register with a program designed to ensure the safe use of the drug.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
